Cat. No.: HY-N6829

Retusin

Name: Retusin
Brand: MedChemExpress
SKU: HY-N6829
Price: 100.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Quercetin-3,3',4',7-tetramethylether)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC₅₀ values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•⁺ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.30%
CAS No.: 1245-15-4
Formule: C₁₉H₁₈O₇
Masse moléculaire:358.34

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Retusin Chemical Structure

CAS No.: 1245-15-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

HY-N6829R

Retusin (Standard)

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	>100 μM Compound: 3, Pque	Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
2008	IC₅₀	50 μM Compound: 17	Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay	[PMID: 21354800]
A2780 ADR	IC₅₀	12 μM Compound: 17	Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay	[PMID: 21354800]
A-375	IC₅₀	69.72 μM Compound: 3, Pque	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	57.54 μM Compound: 3, Pque	Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	82.25 μM Compound: 3, Pque	Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A549	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human A549 cells by HTS assay Anticancer activity against human A549 cells by HTS assay	[PMID: 25139569]
BXPC-3	IC₅₀	>100 μM Compound: 3, Pque	Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C13	IC₅₀	>100 μM Compound: 3, Pque	Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
Calu-1	IC₅₀	6.53 μM Compound: 7a	Anticancer activity against human Calu1 cells by HTS assay Anticancer activity against human Calu1 cells by HTS assay	[PMID: 25139569]
HCT-15	IC₅₀	68.11 μM Compound: 3, Pque	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK293	IC₅₀	141.87 μM Compound: 3, Pque	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HeLa	IC₅₀	46.37 μM Compound: 7a	Anticancer activity against human HeLa cells by HTS assay Anticancer activity against human HeLa cells by HTS assay	[PMID: 25139569]
HL-60	IC₅₀	28 μM Compound: 19	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25014747]
HOP-62	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human HOP62 cells by HTS assay Anticancer activity against human HOP62 cells by HTS assay	[PMID: 25139569]
KB	ED₅₀	>25 μg/mL Compound: retusin	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 1955888]
KB	ED₅₀	41 μg/mL Compound: NSC-61837	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
L929	IC₅₀	>100 μM Compound: 9, 3,7,3',4'-tetra-O-methylated quercetin	Cytotoxicity against mouse L929 cells after 5 days by MTS assay Cytotoxicity against mouse L929 cells after 5 days by MTS assay	[PMID: 22743241]
LOX IMVI	IC₅₀	0.39 μM Compound: 7a	Anticancer activity against human LOXIMVI cells by HTS assay Anticancer activity against human LOXIMVI cells by HTS assay	[PMID: 25139569]
M14	IC₅₀	0.38 μM Compound: 7a	Anticancer activity against human M14 cells by HTS assay Anticancer activity against human M14 cells by HTS assay	[PMID: 25139569]
MCF7	IC₅₀	>100 μM Compound: 3, Pque	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
MCF7	IC₅₀	0.9 μM Compound: 17	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	0.39 μM Compound: 17	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	16 μM Compound: 17	Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry	[PMID: 21354800]
MDCK-II	IC₅₀	0.54 μM Compound: 12	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay	[PMID: 23851114]
MDCK-II	IC₅₀	0.57 μM Compound: 12	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry	[PMID: 23851114]
NCI/ADR-RES	IC₅₀	>100 μM Compound: 3, Pque	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
NCI-H1299	IC₅₀	10.46 μM Compound: 7a	Anticancer activity against human H1299 cells by HTS assay Anticancer activity against human H1299 cells by HTS assay	[PMID: 25139569]
NCI-H157	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human NCI-H157 cells by HTS assay Anticancer activity against human NCI-H157 cells by HTS assay	[PMID: 25139569]
NCI-H1792	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human NCI-H1792 cells by HTS assay Anticancer activity against human NCI-H1792 cells by HTS assay	[PMID: 25139569]
NCI-H1944	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human NCI-H1944 cells by HTS assay Anticancer activity against human NCI-H1944 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human H460 cells by HTS assay Anticancer activity against human H460 cells by HTS assay	[PMID: 25139569]
NCI-H522	IC₅₀	>50 μM Compound: 7a	Anticancer activity against human NCI-H522 cells by HTS assay Anticancer activity against human NCI-H522 cells by HTS assay	[PMID: 25139569]
Neutrophil	IC₅₀	1.43 μg/mL Compound: 10	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation	[PMID: 18163582]
Neutrophil	IC₅₀	1.69 μg/mL Compound: 10	Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release	[PMID: 18163582]

In Vitro

Retusin (20-80 μM; 48 h) reduces the viability of B16F10 mouse melanoma cells to 35.7% (40 μM) and 3.2% (80 μM) of that in the control group, while decreasing the viability of HaCaT human keratinocytes to 99.2% (20 μM) and 40.4% (40 μM) of the control level^[1].
Retusin (10 μM; 48 h) reduces α-MSH-induced melanin production to 56.6% of that in the control group and decreases cellular tyrosinase activity to 49.9% of the control level in B16F10 mouse melanoma cells^[1].
Retusin (0.1-10 μM; 24 h) considerably increases the percentage of live Neuro-2a cells and decreases the number of early apoptotic cells^[2].
Retusin (24-48 h) potently inhibits Aspergillus niger with an MIC of 100 μg/mL; at a concentration of 100 μg/mL, this compound shows no activity against the tested bacteria, other fungi or yeasts^[4].
Retusin (0.01-10 μM; 24 h) potently inhibits SARS-CoV-2 replication in Vero E6 cells, with an EC₅₀ of 0.4 μM^[5].
Retusin (0.01-10 μM; 48 h) potently inhibits SARS-CoV-2 replication in Calu-3 cells, with an EC₅₀ of 0.6 μM^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

B16F10 murine melanoma cells, HaCaT human keratinocytes
Concentration:

40 μM (B16F10 cells); 80 μM (B16F10 cells); 20 μM (HaCaT cells); 40 μM (HaCaT cells)
Incubation Time:

48 h
Result:

Reduced B16F10 cell viability to 35.7% of control at 40 μM and 3.2% of control at 80 μM.
Reduced HaCaT cell viability to 99.2% of control at 20 μM and 40.4% of control at 40 μM.

Apoptosis Analysis^[2]

Cell Line:

Neuro-2a cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Significantly alleviated the apoptosis damage of Neuro-2a cells induced by 6-OHDA (HY-B1081).

In Vivo

Retusin (10-50 mg/kg; i.p.; single dose) dose-dependently inhibits Copper sulfate (HY-Y1878)-induced emesis in young chicks, with a maximum 45.6% inhibition at 50 mg/kg^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Young male chicks (4 days of age, 25-35 g)^[3]
Dosage:

10 mg/kg; 20 mg/kg; 50 mg/kg
Administration:

i.p.; single dose
Result:

Reduced the mean number of retches to 49.0 (27.4% inhibition vs control).
Reduced the mean number of retches to 48.0 (28.9% inhibition vs control).
Reduced the mean number of retches to 36.7 (45.6% inhibition vs control).

Chemical Information

CAS No. 1245-15-4
Appearance Solid
Masse moléculaire 358.34
Formule C₁₉H₁₈O₇
Color Light yellow to yellow
SMILES

O=C1C(OC)=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(OC)=CC(O)=C13
Synonyms

Quercetin-3,3',4',7-tetramethylether
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Monophenols
Initial Source
- Plants
- Labiatae
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Nat Biomed Eng

DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease. [Abstract]

2026 Apr 24. PMID: 42032039

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (69.77 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7906 mL

13.9532 mL

27.9065 mL

5 mM

0.5581 mL

2.7906 mL

5.5813 mL

10 mM

0.2791 mL

1.3953 mL

2.7906 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (279 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Lu TM, et al. Free-Radical-Scavenging, Antityrosinase, and Cellular Melanogenesis Inhibitory Activities of Synthetic Isoflavones. Chem Biodivers. 2015;12(6):963-979. [Content Brief]

[2]. Tarbeeva DV, et al. Polyphenols from Maackia amurensis Heartwood Protect Neuronal Cells from Oxidative Stress and Prevent Herpetic Infection. Int J Mol Sci. 2024 Apr 9;25(8):4142.
[Content Brief]

[3]. Yang Y, et al. Anti-emetic principles of Pogostemon cablin (Blanco) Benth. Phytomedicine. 1999;6(2):89-93. [Content Brief]

[4]. Tarbeeva DV, et al. Heartwood Protect Neuronal Cells from Oxidative Stress and Prevent Herpetic Infection. Int J Mol Sci. 2024 Apr 9;25(8):4142.
[Content Brief]

[5]. Leal CM, et al. Flavonoids from Siparuna cristata as Potential Inhibitors of SARS-CoV-2 Replication. Rev Bras Farmacogn. 2021;31(5):658-666.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7906 mL	13.9532 mL	27.9065 mL	69.7661 mL
	5 mM	0.5581 mL	2.7906 mL	5.5813 mL	13.9532 mL
	10 mM	0.2791 mL	1.3953 mL	2.7906 mL	6.9766 mL
	15 mM	0.1860 mL	0.9302 mL	1.8604 mL	4.6511 mL
	20 mM	0.1395 mL	0.6977 mL	1.3953 mL	3.4883 mL
	25 mM	0.1116 mL	0.5581 mL	1.1163 mL	2.7906 mL
	30 mM	0.0930 mL	0.4651 mL	0.9302 mL	2.3255 mL
	40 mM	0.0698 mL	0.3488 mL	0.6977 mL	1.7442 mL
	50 mM	0.0558 mL	0.2791 mL	0.5581 mL	1.3953 mL
	60 mM	0.0465 mL	0.2326 mL	0.4651 mL	1.1628 mL

Bioz

Retusin

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Retusin

Retusin (Standard)

Publications Citing Use of MedChemExpress (MCE) Retusin

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Retusin Related Classifications

HY-N6829 Related Classifications

Bioz